Evaluation of PCV15 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans
The investigators will evaluate the immune response of immunocompromised adults, who have previously received at least 1 dose of 23-valent pneumococcal polysaccharide vaccine, to the booster series of 15-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine 8 weeks later. Immune response will be assessed by opsonophagocytic assay reactivity and IgG Geometric mean concentration changes.
- EligibilityCriteria: Inclusion Criteria:  Subject meets the CDC definition of an immunocompromising condition  o chronic renal failure, congenital or acquired asplenia, generalized malignancy, HIV infection, Hodgkin disease, iatrogenic immunosuppression, leukemia, lymphoma, multiple myeloma, nephrotic syndrome, sickle cell disease or other hemoglobinopathies, and solid organ transplant.  Have received at least 1 dose of PPSV23  Exclusion Criteria:  Less than 5 years since last receipt of PPSV23 validated to patient medical record and Immunize Nevada Website Previous administration of PCV20 Previous administration of PCV13 Less than 14 days since administration of any COVID19 vaccination Previous history of Invasive Pneumococcal Disease (IPD) Antibiotic treatment within the previous 90 days - HealthyVolunteers: No - Gender: All - StdAgeList: Child, Adult, Older Adult